相关实验视频

Updated: Jun 6, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

非小细胞肺癌非特异性亚型的生物学和临床特征

Xiaohong Xie¹, Chen Zeng¹, Fei Wang¹

¹The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine,National Clinical Research Center for Respiratory Disease,State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, 510000, China.

|November 25, 2024

概括

非小细胞肺癌-未另有说明 (NSCLC-NOS) 主要影响男性吸烟者,并且通常在晚期被诊断出来. 帕克利塔克塞尔与免疫疗法结合显示为一线治疗的前景,解剖位置和免疫疗法使用会影响预后.

科学领域:

在瘤学瘤学.
病理学病理学病理学
遗传学是一个遗传学.

背景情况:

非小细胞肺癌-未另有说明 (NSCLC-NOS) 是一种罕见的亚型,缺乏特定的形态或染色分类.
这项研究调查了NSCLC-NOS的临床,生物,病理,治疗和预后方面.

研究的目的:

为了探索NSCLC-NOS的特征.
确定NSCLC-NOS的预后因素和最佳的第一线治疗方法.

主要方法:

在2010-2022年间诊断的105名NSCLC-NOS患者的回顾性分析.
临床特征,基因表达和一线治疗的评估.
卡普兰-梅尔,日志等级和考克斯回归分析用于生存和预后因素评估.

主要成果:

NSCLC-NOS患者主要是男性吸烟者,在晚期被诊断出来,驱动基因突变率低 (20.5%).
与佩米特雷克塞德相比,基于帕克利塔塞尔的化疗,特别是与免疫疗法结合使用,显示出更高的客观反应率和更好的无进展生存率.
解剖位置和免疫治疗的使用被确定为总体生存的显著预后因素.

结论:

NSCLC-NOS的特点是男性占主导地位,吸烟史,诊断时晚期,以及低突变率.
帕克利塔塞尔与免疫疗法结合可能为NSCLC-NOS提供优越的第一线治疗效益.
解剖位置和免疫治疗是NSCLC-NOS的关键预后指标.

关键词:

生物特征生物特征临床特征临床特征非小细胞肺癌-未另有说明预测因素是一个预测因素.治疗方法治疗方法

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...